| HOME >> MEDICINE >> TECHNOLOGY |
29,945,191
27,516,458Consolidated Statements of Cash Flows(Unaudited)For the Three Months EndedSeptember 30,20102009Cash flows from operating activities:Net Income
$ 3,669,691
$ 2,186,722Adjustments to reconcile net income to net cash provided by (used in) operating activities:Depreciation and amortization
314,116
197,037Share-based payments
1,269,170
512,209Loss on disposal of fixed assets
-
39,502Changes in current assets and current liabilities:Accounts receivable
(843,012)
(1,492,362)Inventory
(1,552,067)
126,979Other current assets
(93,032)
419,905Accounts payable and accrued expenses
(189,572)
183,242Accounts payable – construction related
(1,139,900)
-VAT taxes payable
(111,405)
16,025Income tax payable
40,316
19,054Other taxes payable
66,462
(433)Dividends payable
(18,138)
-Other current liabilities
133,153
33,582Total adjustments(2,123,909)54,740Net cash provided by operating activities1,545,7822,241,462Cash flows from investing activities:Additions to property and equipment
(1,922,700)
(525,965)Additions to intangible assets – drug
-
(1,891,269)Loan receivable
-
(293,220)Net cash used in investing activities(1,922,700)(2,710,454)Cash flows from financing activities:Additional paid-in capital
-
2,534,581Contribution from minority shareholders
-
439,830Dividends paid
(54,857)
(499,331)Net cash provided by (used in) financing activities(54,857)2,475,080Effect of foreign currency translation on cash311,912(5,435)Net i
'/>"/>
| SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2010 PR Newswire. All rights reserved |